Loading…

Thrombolytic therapy for central venous catheter occlusion

Long-term central venous catheters have improved the quality of care for patients with chronic illnesses, but are complicated by obstructions which can result in delay of treatment or catheter removal. This paper reviews thrombolytic treatment for catheter obstruction. Literature from Medline search...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) 2012-05, Vol.97 (5), p.641-650
Main Authors: BASKIN, Jacquelyn L, REISS, Ulrike, WILIMAS, Judith A, METZGER, Monika L, RIBEIRO, Raul C, PUI, Ching-Hon, HOWARD, Scott C
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c534t-e55d44064c1b97a315216a41d2f5d5322e4a8d54953213ed67184dd353e9a0cf3
cites
container_end_page 650
container_issue 5
container_start_page 641
container_title Haematologica (Roma)
container_volume 97
creator BASKIN, Jacquelyn L
REISS, Ulrike
WILIMAS, Judith A
METZGER, Monika L
RIBEIRO, Raul C
PUI, Ching-Hon
HOWARD, Scott C
description Long-term central venous catheters have improved the quality of care for patients with chronic illnesses, but are complicated by obstructions which can result in delay of treatment or catheter removal. This paper reviews thrombolytic treatment for catheter obstruction. Literature from Medline searches using the terms "central venous catheter", "central venous access device" OR "central venous line" associated with the terms "obstruction", "occlusion" OR "thrombolytic" was reviewed. Efficacy of thrombolytic therapy, central venous catheter clearance rates and time to clearance were assessed. Alteplase, one of the current therapies, clears 52% of obstructed catheters within 30 min with 86% overall clearance (after 2 doses, when necessary). However, newer medications may have higher efficacy or shorter time to clearance. Reteplase cleared 67-74% within 30-40 min and 95% of catheters overall. Occlusions were resolved in 70 and 83% of patients with one and 2 doses of tenecteplase, respectively. Recombinant urokinase cleared 60% of catheters at 30 min and 73% overall. Alfimeprase demonstrated rapid catheter clearance with resolution in 40% of subjects within 5 min, 60% within 30 min, and 80% within 2 h. Additionally, urokinase prophylaxis decreased the incidence of catheter occlusions from 16-68% in the control group to 4-23% in the treatment group; in some studies, rates of catheter infections were also decreased in the urokinase group. Thrombolytic agents successfully clear central venous catheter occlusions in most cases. Newer agents may act more rapidly and effectively than currently utilized therapies, but randomized studies with direct comparisons of these agents are needed to determine optimal management for catheter obstruction.
doi_str_mv 10.3324/haematol.2011.050492
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7bace4ae66ba4bcb8ff92b5241b2a320</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7bace4ae66ba4bcb8ff92b5241b2a320</doaj_id><sourcerecordid>1011190501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-e55d44064c1b97a315216a41d2f5d5322e4a8d54953213ed67184dd353e9a0cf3</originalsourceid><addsrcrecordid>eNpVkU1v3CAQhlHVqtmm_QdV5UulXryFAWzTQ6Uo6kekSL2kZzQGvCbCZgverPbfl3Q3aXICMe88DDyEvGd0zTmIzyO6CZcY1kAZW1NJhYIXZMWkgrprgb0kK8oVrRvadmfkTc63lAJVqn1NzgBYRwXQFflyM6Y49TEcFm-qZXQJt4dqiKkybl4ShurOzXGXK4OluLhURWPCLvs4vyWvBgzZvTut5-T39283lz_r618_ri4vrmsjuVhqJ6UVgjbCsF61yJkE1qBgFgZpJQdwAjsrhSp7xp1tWtYJa7nkTiE1Az8nV0eujXirt8lPmA46otf_DmLaaExl-uB026MpONc0PYre9N0wKOglCNYDcqCF9fXI2u76ydnTG59Bn1dmP-pNvNOcC1CNKIBPJ0CKf3YuL3ry2bgQcHblmzQrMpgqNliJimPUpJhzcsPjNYzqe4X6QaG-V6iPCkvbh6cjPjY9OCuBj6cAZoNhSDgbn__npOKybZ7kRr8Z9z45nScMoWBB7_d71WqpG8H4X4U0tD8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1011190501</pqid></control><display><type>article</type><title>Thrombolytic therapy for central venous catheter occlusion</title><source>Freely Accessible Science Journals</source><source>PubMed Central</source><creator>BASKIN, Jacquelyn L ; REISS, Ulrike ; WILIMAS, Judith A ; METZGER, Monika L ; RIBEIRO, Raul C ; PUI, Ching-Hon ; HOWARD, Scott C</creator><creatorcontrib>BASKIN, Jacquelyn L ; REISS, Ulrike ; WILIMAS, Judith A ; METZGER, Monika L ; RIBEIRO, Raul C ; PUI, Ching-Hon ; HOWARD, Scott C</creatorcontrib><description>Long-term central venous catheters have improved the quality of care for patients with chronic illnesses, but are complicated by obstructions which can result in delay of treatment or catheter removal. This paper reviews thrombolytic treatment for catheter obstruction. Literature from Medline searches using the terms "central venous catheter", "central venous access device" OR "central venous line" associated with the terms "obstruction", "occlusion" OR "thrombolytic" was reviewed. Efficacy of thrombolytic therapy, central venous catheter clearance rates and time to clearance were assessed. Alteplase, one of the current therapies, clears 52% of obstructed catheters within 30 min with 86% overall clearance (after 2 doses, when necessary). However, newer medications may have higher efficacy or shorter time to clearance. Reteplase cleared 67-74% within 30-40 min and 95% of catheters overall. Occlusions were resolved in 70 and 83% of patients with one and 2 doses of tenecteplase, respectively. Recombinant urokinase cleared 60% of catheters at 30 min and 73% overall. Alfimeprase demonstrated rapid catheter clearance with resolution in 40% of subjects within 5 min, 60% within 30 min, and 80% within 2 h. Additionally, urokinase prophylaxis decreased the incidence of catheter occlusions from 16-68% in the control group to 4-23% in the treatment group; in some studies, rates of catheter infections were also decreased in the urokinase group. Thrombolytic agents successfully clear central venous catheter occlusions in most cases. Newer agents may act more rapidly and effectively than currently utilized therapies, but randomized studies with direct comparisons of these agents are needed to determine optimal management for catheter obstruction.</description><identifier>ISSN: 0390-6078</identifier><identifier>EISSN: 1592-8721</identifier><identifier>DOI: 10.3324/haematol.2011.050492</identifier><identifier>PMID: 22180420</identifier><language>eng</language><publisher>Pavia: Ferrata Storti Foundation</publisher><subject>Biological and medical sciences ; Catheterization, Central Venous - adverse effects ; Fibrinolytic Agents - therapeutic use ; Hematologic and hematopoietic diseases ; Humans ; Medical sciences ; Review ; Thrombolytic Therapy ; Venous Thrombosis - etiology ; Venous Thrombosis - therapy</subject><ispartof>Haematologica (Roma), 2012-05, Vol.97 (5), p.641-650</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright© Ferrata Storti Foundation 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-e55d44064c1b97a315216a41d2f5d5322e4a8d54953213ed67184dd353e9a0cf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342964/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342964/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=25935760$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22180420$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BASKIN, Jacquelyn L</creatorcontrib><creatorcontrib>REISS, Ulrike</creatorcontrib><creatorcontrib>WILIMAS, Judith A</creatorcontrib><creatorcontrib>METZGER, Monika L</creatorcontrib><creatorcontrib>RIBEIRO, Raul C</creatorcontrib><creatorcontrib>PUI, Ching-Hon</creatorcontrib><creatorcontrib>HOWARD, Scott C</creatorcontrib><title>Thrombolytic therapy for central venous catheter occlusion</title><title>Haematologica (Roma)</title><addtitle>Haematologica</addtitle><description>Long-term central venous catheters have improved the quality of care for patients with chronic illnesses, but are complicated by obstructions which can result in delay of treatment or catheter removal. This paper reviews thrombolytic treatment for catheter obstruction. Literature from Medline searches using the terms "central venous catheter", "central venous access device" OR "central venous line" associated with the terms "obstruction", "occlusion" OR "thrombolytic" was reviewed. Efficacy of thrombolytic therapy, central venous catheter clearance rates and time to clearance were assessed. Alteplase, one of the current therapies, clears 52% of obstructed catheters within 30 min with 86% overall clearance (after 2 doses, when necessary). However, newer medications may have higher efficacy or shorter time to clearance. Reteplase cleared 67-74% within 30-40 min and 95% of catheters overall. Occlusions were resolved in 70 and 83% of patients with one and 2 doses of tenecteplase, respectively. Recombinant urokinase cleared 60% of catheters at 30 min and 73% overall. Alfimeprase demonstrated rapid catheter clearance with resolution in 40% of subjects within 5 min, 60% within 30 min, and 80% within 2 h. Additionally, urokinase prophylaxis decreased the incidence of catheter occlusions from 16-68% in the control group to 4-23% in the treatment group; in some studies, rates of catheter infections were also decreased in the urokinase group. Thrombolytic agents successfully clear central venous catheter occlusions in most cases. Newer agents may act more rapidly and effectively than currently utilized therapies, but randomized studies with direct comparisons of these agents are needed to determine optimal management for catheter obstruction.</description><subject>Biological and medical sciences</subject><subject>Catheterization, Central Venous - adverse effects</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Review</subject><subject>Thrombolytic Therapy</subject><subject>Venous Thrombosis - etiology</subject><subject>Venous Thrombosis - therapy</subject><issn>0390-6078</issn><issn>1592-8721</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1v3CAQhlHVqtmm_QdV5UulXryFAWzTQ6Uo6kekSL2kZzQGvCbCZgverPbfl3Q3aXICMe88DDyEvGd0zTmIzyO6CZcY1kAZW1NJhYIXZMWkgrprgb0kK8oVrRvadmfkTc63lAJVqn1NzgBYRwXQFflyM6Y49TEcFm-qZXQJt4dqiKkybl4ShurOzXGXK4OluLhURWPCLvs4vyWvBgzZvTut5-T39283lz_r618_ri4vrmsjuVhqJ6UVgjbCsF61yJkE1qBgFgZpJQdwAjsrhSp7xp1tWtYJa7nkTiE1Az8nV0eujXirt8lPmA46otf_DmLaaExl-uB026MpONc0PYre9N0wKOglCNYDcqCF9fXI2u76ydnTG59Bn1dmP-pNvNOcC1CNKIBPJ0CKf3YuL3ry2bgQcHblmzQrMpgqNliJimPUpJhzcsPjNYzqe4X6QaG-V6iPCkvbh6cjPjY9OCuBj6cAZoNhSDgbn__npOKybZ7kRr8Z9z45nScMoWBB7_d71WqpG8H4X4U0tD8</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>BASKIN, Jacquelyn L</creator><creator>REISS, Ulrike</creator><creator>WILIMAS, Judith A</creator><creator>METZGER, Monika L</creator><creator>RIBEIRO, Raul C</creator><creator>PUI, Ching-Hon</creator><creator>HOWARD, Scott C</creator><general>Ferrata Storti Foundation</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20120501</creationdate><title>Thrombolytic therapy for central venous catheter occlusion</title><author>BASKIN, Jacquelyn L ; REISS, Ulrike ; WILIMAS, Judith A ; METZGER, Monika L ; RIBEIRO, Raul C ; PUI, Ching-Hon ; HOWARD, Scott C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-e55d44064c1b97a315216a41d2f5d5322e4a8d54953213ed67184dd353e9a0cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Biological and medical sciences</topic><topic>Catheterization, Central Venous - adverse effects</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Review</topic><topic>Thrombolytic Therapy</topic><topic>Venous Thrombosis - etiology</topic><topic>Venous Thrombosis - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BASKIN, Jacquelyn L</creatorcontrib><creatorcontrib>REISS, Ulrike</creatorcontrib><creatorcontrib>WILIMAS, Judith A</creatorcontrib><creatorcontrib>METZGER, Monika L</creatorcontrib><creatorcontrib>RIBEIRO, Raul C</creatorcontrib><creatorcontrib>PUI, Ching-Hon</creatorcontrib><creatorcontrib>HOWARD, Scott C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Haematologica (Roma)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BASKIN, Jacquelyn L</au><au>REISS, Ulrike</au><au>WILIMAS, Judith A</au><au>METZGER, Monika L</au><au>RIBEIRO, Raul C</au><au>PUI, Ching-Hon</au><au>HOWARD, Scott C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thrombolytic therapy for central venous catheter occlusion</atitle><jtitle>Haematologica (Roma)</jtitle><addtitle>Haematologica</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>97</volume><issue>5</issue><spage>641</spage><epage>650</epage><pages>641-650</pages><issn>0390-6078</issn><eissn>1592-8721</eissn><abstract>Long-term central venous catheters have improved the quality of care for patients with chronic illnesses, but are complicated by obstructions which can result in delay of treatment or catheter removal. This paper reviews thrombolytic treatment for catheter obstruction. Literature from Medline searches using the terms "central venous catheter", "central venous access device" OR "central venous line" associated with the terms "obstruction", "occlusion" OR "thrombolytic" was reviewed. Efficacy of thrombolytic therapy, central venous catheter clearance rates and time to clearance were assessed. Alteplase, one of the current therapies, clears 52% of obstructed catheters within 30 min with 86% overall clearance (after 2 doses, when necessary). However, newer medications may have higher efficacy or shorter time to clearance. Reteplase cleared 67-74% within 30-40 min and 95% of catheters overall. Occlusions were resolved in 70 and 83% of patients with one and 2 doses of tenecteplase, respectively. Recombinant urokinase cleared 60% of catheters at 30 min and 73% overall. Alfimeprase demonstrated rapid catheter clearance with resolution in 40% of subjects within 5 min, 60% within 30 min, and 80% within 2 h. Additionally, urokinase prophylaxis decreased the incidence of catheter occlusions from 16-68% in the control group to 4-23% in the treatment group; in some studies, rates of catheter infections were also decreased in the urokinase group. Thrombolytic agents successfully clear central venous catheter occlusions in most cases. Newer agents may act more rapidly and effectively than currently utilized therapies, but randomized studies with direct comparisons of these agents are needed to determine optimal management for catheter obstruction.</abstract><cop>Pavia</cop><pub>Ferrata Storti Foundation</pub><pmid>22180420</pmid><doi>10.3324/haematol.2011.050492</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0390-6078
ispartof Haematologica (Roma), 2012-05, Vol.97 (5), p.641-650
issn 0390-6078
1592-8721
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_7bace4ae66ba4bcb8ff92b5241b2a320
source Freely Accessible Science Journals; PubMed Central
subjects Biological and medical sciences
Catheterization, Central Venous - adverse effects
Fibrinolytic Agents - therapeutic use
Hematologic and hematopoietic diseases
Humans
Medical sciences
Review
Thrombolytic Therapy
Venous Thrombosis - etiology
Venous Thrombosis - therapy
title Thrombolytic therapy for central venous catheter occlusion
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A24%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thrombolytic%20therapy%20for%20central%20venous%20catheter%20occlusion&rft.jtitle=Haematologica%20(Roma)&rft.au=BASKIN,%20Jacquelyn%20L&rft.date=2012-05-01&rft.volume=97&rft.issue=5&rft.spage=641&rft.epage=650&rft.pages=641-650&rft.issn=0390-6078&rft.eissn=1592-8721&rft_id=info:doi/10.3324/haematol.2011.050492&rft_dat=%3Cproquest_doaj_%3E1011190501%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c534t-e55d44064c1b97a315216a41d2f5d5322e4a8d54953213ed67184dd353e9a0cf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1011190501&rft_id=info:pmid/22180420&rfr_iscdi=true